Rigel Announces U.S. FDA Approval of REZLIDHIA(TM) (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Stock Information for Rigel Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rigel Pharmaceuticals Inc.

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Rigel Pharmaceuticals Provides Business Update
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.